Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arista Networks, Inc. stock logo
ANET
Arista Networks
$86.79
-0.8%
$102.03
$60.08
$133.58
$109.35B1.088.57 million shs4.69 million shs
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
$47.55
$47.31
$15.08
$47.90
$2.27B1.031.03 million shsN/A
Equifax Inc. stock logo
EFX
Equifax
$243.98
-0.6%
$252.91
$213.02
$309.63
$30.27B1.65919,867 shs856,289 shs
EVO Payments, Inc. stock logo
EVOP
EVO Payments
$33.99
$33.91
$21.01
$34.01
$1.76B1.11668,889 shsN/A
Global Payments Inc. stock logo
GPN
Global Payments
$98.88
-0.1%
$104.49
$90.99
$136.36
$24.26B1.042.08 million shs659,043 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$851.63
-1.5%
$837.36
$711.40
$972.53
$806.77B0.343.15 million shs1.32 million shs
PayPal Holdings, Inc. stock logo
PYPL
PayPal
$70.69
-0.4%
$77.93
$56.97
$93.66
$69.87B1.5210.91 million shs3.71 million shs
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
$22.47
-2.6%
$22.02
$3.77
$28.00
$56.40M4.1262,902 shs83,600 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arista Networks, Inc. stock logo
ANET
Arista Networks
+5.19%+2.96%-10.91%-23.61%+14.32%
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
0.00%0.00%0.00%0.00%0.00%
Equifax Inc. stock logo
EFX
Equifax
+0.50%+2.00%+3.04%-6.12%-7.15%
EVO Payments, Inc. stock logo
EVOP
EVO Payments
0.00%0.00%0.00%0.00%0.00%
Global Payments Inc. stock logo
GPN
Global Payments
+2.16%+3.45%-3.93%-12.26%-24.97%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+3.16%+4.90%-0.94%+8.83%+12.37%
PayPal Holdings, Inc. stock logo
PYPL
PayPal
+1.11%+1.90%-5.31%-19.58%+9.57%
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
0.00%0.00%0.00%0.00%0.00%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arista Networks, Inc. stock logo
ANET
Arista Networks
4.8832 of 5 stars
4.43.00.03.62.92.52.5
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Equifax Inc. stock logo
EFX
Equifax
4.7137 of 5 stars
3.43.01.74.13.31.71.9
EVO Payments, Inc. stock logo
EVOP
EVO Payments
N/AN/AN/AN/AN/AN/AN/AN/A
Global Payments Inc. stock logo
GPN
Global Payments
4.9725 of 5 stars
4.33.02.52.33.01.73.8
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.6205 of 5 stars
2.43.03.34.02.92.51.9
PayPal Holdings, Inc. stock logo
PYPL
PayPal
4.8602 of 5 stars
4.33.00.03.22.92.52.5
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arista Networks, Inc. stock logo
ANET
Arista Networks
2.73
Moderate Buy$114.0031.35% Upside
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
0.00
N/AN/AN/A
Equifax Inc. stock logo
EFX
Equifax
2.84
Moderate Buy$298.5622.37% Upside
EVO Payments, Inc. stock logo
EVOP
EVO Payments
0.00
N/AN/AN/A
Global Payments Inc. stock logo
GPN
Global Payments
2.50
Moderate Buy$134.3335.85% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7218.56% Upside
PayPal Holdings, Inc. stock logo
PYPL
PayPal
2.63
Moderate Buy$90.0327.36% Upside
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest LLY, ANET, GPN, DICE, SGTX, PYPL, EFX, and EVOP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/20/2025
Equifax Inc. stock logo
EFX
Equifax
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Outperform$300.00
3/17/2025
Arista Networks, Inc. stock logo
ANET
Arista Networks
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/14/2025
Equifax Inc. stock logo
EFX
Equifax
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$265.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Arista Networks, Inc. stock logo
ANET
Arista Networks
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$112.00 ➝ $115.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/3/2025
Arista Networks, Inc. stock logo
ANET
Arista Networks
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/3/2025
Arista Networks, Inc. stock logo
ANET
Arista Networks
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
3/3/2025
Arista Networks, Inc. stock logo
ANET
Arista Networks
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
2/28/2025
PayPal Holdings, Inc. stock logo
PYPL
PayPal
DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$92.00
2/26/2025
PayPal Holdings, Inc. stock logo
PYPL
PayPal
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$85.00 ➝ $76.00
(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arista Networks, Inc. stock logo
ANET
Arista Networks
$7.00B15.63$1.84 per share47.08$7.93 per share10.95
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
$1.13M2,008.50N/AN/A$10.86 per share4.38
Equifax Inc. stock logo
EFX
Equifax
$5.68B5.33$12.98 per share18.80$38.84 per share6.28
EVO Payments, Inc. stock logo
EVOP
EVO Payments
$543.08M3.24$1.75 per share19.41($21.85) per share-1.56
Global Payments Inc. stock logo
GPN
Global Payments
$10.11B2.41$17.72 per share5.58$92.30 per share1.07
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.93$13.88 per share61.34$15.05 per share56.59
PayPal Holdings, Inc. stock logo
PYPL
PayPal
$31.80B2.20$5.09 per share13.88$20.64 per share3.43
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
$12.94M4.36N/AN/A$15.68 per share1.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arista Networks, Inc. stock logo
ANET
Arista Networks
$2.85B$2.2239.0633.643.1040.72%29.91%21.67%5/6/2025 (Estimated)
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
-$83.89M-$2.34N/AN/AN/AN/A-22.01%-20.79%N/A
Equifax Inc. stock logo
EFX
Equifax
$604.10M$4.8350.5224.592.7910.63%19.13%7.51%4/16/2025 (Estimated)
EVO Payments, Inc. stock logo
EVOP
EVO Payments
$5.28M-$0.12N/AN/A0.97%-7.74%3.67%N/A
Global Payments Inc. stock logo
GPN
Global Payments
$1.57B$6.1815.977.330.8615.54%12.21%5.64%4/29/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7172.6627.371.4023.51%85.24%16.19%4/29/2025 (Estimated)
PayPal Holdings, Inc. stock logo
PYPL
PayPal
$4.15B$4.0117.6112.561.2713.04%23.67%5.83%4/29/2025 (Estimated)
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
-$43.56M-$12.23N/AN/AN/A-171.29%-83.07%-38.17%N/A

Latest LLY, ANET, GPN, DICE, SGTX, PYPL, EFX, and EVOP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2025N/A
Equifax Inc. stock logo
EFX
Equifax
$1.45N/AN/AN/A$1.41 billionN/A
2/18/2025Q4 2024
Arista Networks, Inc. stock logo
ANET
Arista Networks
$0.57$0.59+$0.02$0.62$1.90 billion$1.93 billion
2/13/2025Q4 2024
Global Payments Inc. stock logo
GPN
Global Payments
$2.98$2.84-$0.14$2.25$2.31 billion$2.29 billion
2/6/2025Q4 2024
Equifax Inc. stock logo
EFX
Equifax
$2.12$2.12N/A$1.39$1.44 billionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/4/2025Q4 2024
PayPal Holdings, Inc. stock logo
PYPL
PayPal
$1.11$1.19+$0.08$1.11$8.27 billion$8.37 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arista Networks, Inc. stock logo
ANET
Arista Networks
N/AN/AN/AN/AN/A
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
N/AN/AN/AN/AN/A
Equifax Inc. stock logo
EFX
Equifax
$1.560.64%N/A32.30%N/A
EVO Payments, Inc. stock logo
EVOP
EVO Payments
N/AN/AN/AN/AN/A
Global Payments Inc. stock logo
GPN
Global Payments
$1.001.01%+3.96%16.18%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.70%+15.21%51.24%11 Years
PayPal Holdings, Inc. stock logo
PYPL
PayPal
N/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/AN/AN/AN/AN/A

Latest LLY, ANET, GPN, DICE, SGTX, PYPL, EFX, and EVOP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2025
Global Payments Inc. stock logo
GPN
Global Payments
Quarterly$0.250.96%3/14/20253/14/20253/28/2025
2/5/2025
Equifax Inc. stock logo
EFX
Equifax
quarterly$0.390.58%2/21/20252/21/20253/14/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arista Networks, Inc. stock logo
ANET
Arista Networks
N/A
4.36
3.69
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
N/A
25.88
32.44
Equifax Inc. stock logo
EFX
Equifax
0.90
0.75
0.88
EVO Payments, Inc. stock logo
EVOP
EVO Payments
N/A
1.11
1.10
Global Payments Inc. stock logo
GPN
Global Payments
0.66
0.97
0.93
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
PayPal Holdings, Inc. stock logo
PYPL
PayPal
0.48
1.26
1.26
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/A
1.78
1.78
CompanyEmployeesShares OutstandingFree FloatOptionable
Arista Networks, Inc. stock logo
ANET
Arista Networks
4,4121.26 billion1.22 billionOptionable
DICE Therapeutics, Inc. stock logo
DICE
DICE Therapeutics
7147.73 million45.39 millionNot Optionable
Equifax Inc. stock logo
EFX
Equifax
14,000124.02 million122.01 millionOptionable
EVO Payments, Inc. stock logo
EVOP
EVO Payments
2,40051.74 million45.14 millionNot Optionable
Global Payments Inc. stock logo
GPN
Global Payments
27,000245.88 million245.19 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
PayPal Holdings, Inc. stock logo
PYPL
PayPal
29,900989.24 million987.86 millionOptionable
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
622.51 million2.35 millionNot Optionable

Recent News About These Companies

Lilly & Co Eli's Net Worth
MCRB Seres Therapeutics, Inc.
Beam Therapeutics Inc.
Eli Lilly Concludes Acquisition Of Sigilon Therapeutics
Lilly Completes Acquisition of Sigilon Therapeutics
SGTX - Sigilon Therapeutics, Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arista Networks stock logo

Arista Networks NYSE:ANET

$86.79 -0.72 (-0.82%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arista Networks, Inc. engages in the development, marketing, and sale of data-driven, client to cloud networking solutions for data center, campus, and routing environments in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Its cloud networking solutions consist of Extensible Operating System (EOS), a publish-subscribe state-sharing networking operating system offered in combination with a set of network applications. The company offers data center and cloud networking systems, including newer artificial intelligence (AI) ethernet switching platforms; campus wired and wireless products, and routing systems addressing Core Routing, Edge Routing, Data Center Interconnect (DCI), Multi-cloud and Wide Area Networking (WAN) use cases; and a suite of value-add software solutions that leverage EOS to provide end-to-end orchestration, automation, analytics, network monitoring, and security. It also provides post contract customer support services, such as technical support, hardware repair and replacement parts beyond standard warranty, bug fixes, patches, and upgrade services. The company serves a range of industries comprising internet companies, service providers, financial services organizations, government agencies, media and entertainment companies, telecommunication service providers, and others. It markets and sells its products through distributors, system integrators, value-added resellers, and original equipment manufacturer partners, as well as through its direct sales force. The company was formerly known as Arastra, Inc. and changed its name to Arista Networks, Inc. in October 2008. Arista Networks, Inc. was incorporated in 2004 and is headquartered in Santa Clara, California.

DICE Therapeutics stock logo

DICE Therapeutics NASDAQ:DICE

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Equifax stock logo

Equifax NYSE:EFX

$243.98 -1.38 (-0.56%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Equifax Inc. operates as a data, analytics, and technology company. The company operates through three segments: Workforce Solutions, U.S. Information Solutions (USIS), and International. The Workforce Solutions segment offers services that enables customers to verify income, employment, educational history, criminal justice data, healthcare professional licensure, and sanctions of people in the United States; and employer customers with services that assist them in complying with and automating payroll-related and human resource management processes throughout the entire cycle of the employment relationship. The USIS segment provides consumer and commercial information services, such as credit information and credit scoring, credit modeling and portfolio analytics, locate, fraud detection and prevention, identity verification, and other consulting services; mortgage services; financial marketing services; identity management services; and credit monitoring products. The International segment offers information service products, which include consumer and commercial services, such as credit and financial information, and credit scoring and modeling; and credit and other marketing products and services, as well as offers information, technology, and other services to support debt collections and recovery management. The company serves customers in financial services, mortgage, retail, telecommunications, utilities, automotive, brokerage, healthcare, and insurance industries, as well as government agencies. It operates in Argentina, Australia, Brazil, Canada, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Honduras, India, Ireland, Mexico, New Zealand, Paraguay, Peru, Portugal, Spain, the United Kingdom, Uruguay, and the United States. The company was founded in 1899 and is headquartered in Atlanta, Georgia.

EVO Payments stock logo

EVO Payments NASDAQ:EVOP

EVO Payments, Inc. is a holding company, which provides payment technology and services. The firm offers payment and commerce solutions. It operates through the Americas and Europe geographical segments. The Americas segment consists of the United States, Canada, Mexico, and Chile. The Europe segment includes operations in Poland, Germany, Ireland, the United Kingdom, Spain, and the Czech Republic, as well as support of merchants in surrounding markets. The company was founded by Rafik R. Sidhom in 1989 and is headquartered in Atlanta, GA.

Global Payments stock logo

Global Payments NYSE:GPN

$98.88 -0.13 (-0.13%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Global Payments Inc. provides payment technology and software solutions for card, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through two segments, Merchant Solutions and Issuer Solutions. The Merchant Solutions segment offers authorization, settlement and funding, customer support, chargeback resolution, terminal rental, sales and deployment, payment security, and consolidated billing and reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added solutions and services, such as point-of-sale software, analytics and customer engagement, payroll and reporting, and human capital management. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments, account payables, and electronic payment alternatives solutions for businesses and governments. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$851.63 -13.27 (-1.53%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

PayPal stock logo

PayPal NASDAQ:PYPL

$70.69 -0.28 (-0.39%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PayPal Holdings, Inc. operates a technology platform that enables digital payments on behalf of merchants and consumers worldwide. It operates a two-sided network at scale that connects merchants and consumers that enables its customers to connect, transact, and send and receive payments through online and in person, as well as transfer and withdraw funds using various funding sources, such as bank accounts, PayPal or Venmo account balance, PayPal and Venmo branded credit products comprising its installment products, credit and debit cards, and cryptocurrencies, as well as other stored value products, including gift cards and eligible rewards. The company provides payment solutions under the PayPal, PayPal Credit, Braintree, Venmo, Xoom, Zettle, Hyperwallet, Honey, and Paidy names. The company was founded in 1998 and is headquartered in San Jose, California.

Sigilon Therapeutics stock logo

Sigilon Therapeutics NASDAQ:SGTX

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.